Central vision magnification via optical projection onto healthy retinal tissue

Central vision magnification via optical projection onto healthy retinal tissue describes a therapeutic strategy or technology aimed at improving central vision by optically projecting images onto undamaged areas of the retina. This approach is relevant in conditions where the central retina (such as the fovea) is damaged—commonly seen in diseases like age-related macular degeneration—by redirecting visual information to healthier peripheral retinal regions that retain functional photoreceptors[1]. The phrase refers to an engineering and clinical intervention rather than a discrete biological entity such as a receptor, enzyme, transporter, or gene product. There are no standard abbreviations, aliases, interacting drugs, mechanisms of action for drugs targeting this "target," nor are there established biomarkers or safety concerns specific to this phrase. It does not fit into recognized molecular classifications such as "G protein-coupled receptor," "Ion channel," etc., and should not be considered a canonical therapeutic target according to biomedical conventions.